Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Thermo Fisher Scientific, Inc.

TMONYSEEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.…

Filed Jan 29, 2026Accepted Jan 29, 2026, 6:02 AM ESTCIK 97745Accession 0000097745-26-000012
Share

Company context

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Current securities

Recent company filings

  1. 4 filingSep 1, 2026
  2. 4 filingSep 1, 2026
  3. 4 filingSep 1, 2026
  4. 4 filingSep 1, 2026
  5. 4 filingSep 1, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) q42025earnings8kex99_1.htm

EX-99.1 2 q42025earnings8kex99_1.htm EX-99.1 Document Exhibit 99.1 News Media Contact Information: Investor Contact Information: Sandy Pound Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.pound@thermofisher.com E-mail: rafael.tejada@thermofisher.com Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results WALTHAM, Mass. (January 29, 2026) - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights • Fourth quarter revenue grew 7% to $12.21 billion. • Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. • Fourth quarter adjusted EPS grew 8% to $6.57. • Full year revenue grew 4% to $44.56 billion. • Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. • Full year adjusted EPS grew 5% to $22.87. • Delivered another year of excellent operational performance and share gain reflecting our act…

Open exhibit ↗